Lower TGFß serum levels and higher frequency of IFNγ-producing T cells during early immune reconstitution in surviving children after allogeneic stem cell transplantation

2012 ◽  
Vol 60 (1) ◽  
pp. 121-128 ◽  
Author(s):  
Verena Wiegering ◽  
Beate Winkler ◽  
Imme Haubitz ◽  
Matthias Wölfl ◽  
Paul G. Schlegel ◽  
...  
PLoS ONE ◽  
2017 ◽  
Vol 12 (8) ◽  
pp. e0183828 ◽  
Author(s):  
Kriti Verma ◽  
Nidhi Jyotsana ◽  
Ivonne Buenting ◽  
Susanne Luther ◽  
Angelika Pfanne ◽  
...  

Author(s):  
Hao Dai ◽  
Olaf Penack ◽  
Aleksandar Radujkovic ◽  
David Schult ◽  
Joshua Majer-Lauterbach ◽  
...  

AbstractHyperbilirubinemia occurs frequently after allogeneic stem cell transplantation. Causes include primary liver damage and endothelial complications as major contributors. Here, we have investigated the impact of early bilirubinemia (EB) on posttransplant outcomes. Maximum total bilirubin levels (days 0–28) were categorized using maximally selected log rank statistics to identify a cut off for the endpoint non-relapse mortality (NRM) in a training cohort of 873 patients. EB above this cut off was correlated with NRM and overall survival (OS) and with pre- and posttransplant Angiopoietin-2, interleukin (IL)18, CXCL8 and suppressor of tumorigenicity-2 (ST2) serum levels, and the endothelial activation and stress index (EASIX). Clinical correlations were validated in a sample of 388 patients transplanted in an independent institution. The EB cut off was determined at 3.6 mg/dL (61.6 µM). EB predicted OS (HR 1.60, 95% CI 1.21–2.12, p < 0.001), and NRM (CSHR 2.14; 1.28–3.56, p = 0.004), also independent of typical endothelial complications such as veno-occlusive disease, refractory acute graft-versus-host disease, or transplant-associated microangiopathy. However, EB correlated with high Angiopoietin-2, EASIX-pre and EASIX-day 0, as well as increased levels of posttransplant CXCL8, IL18, and ST2. In summary, EB indicates a poor prognosis. The association of EB with endothelial biomarkers suggests an endothelial pathomechanism also for this posttransplant complication.


Blood ◽  
2013 ◽  
Vol 121 (18) ◽  
pp. 3745-3758 ◽  
Author(s):  
Emily Blyth ◽  
Leighton Clancy ◽  
Renee Simms ◽  
Chun K. K. Ma ◽  
Jane Burgess ◽  
...  

Key Points Infusion of CMV-specific T cells early posttransplant does not increase acute or chronic graft-versus-host disease. CMV-specific T cells early posttransplant reduce the need for pharmacotherapy without increased rates of CMV-related organ damage.


PLoS ONE ◽  
2008 ◽  
Vol 3 (11) ◽  
pp. e3634 ◽  
Author(s):  
Thomas Widmann ◽  
Urban Sester ◽  
Barbara C. Gärtner ◽  
Jörg Schubert ◽  
Michael Pfreundschuh ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document